IRAK-M Inhibitors
IRAK-M inhibitors constitute a class of chemicals designed to modulate the activity of IRAK-M, a critical regulator of the immune response. Among these inhibitors, TAK-242 stands out as a direct inhibitor that disrupts IRAK-M function by preventing its association with Toll-like receptor 4 (TLR4). This interference with TLR4 signaling leads to an enhanced pro-inflammatory state, as IRAK-M's anti-inflammatory role is compromised. BX-795, a TBK1 and IKKε inhibitor, and BAY 11-7082, an NF-κB activation inhibitor, indirectly influence IRAK-M. BX-795 blocks key kinases in the TLR signaling pathway, indirectly reducing IRAK-M expression. BAY 11-7082, on the other hand, prevents NF-κB-dependent transcription of IRAK-M, leading to an enhanced pro-inflammatory response.
Among the direct inhibitors, IRAK Inhibitor I, BI605906, CDD-450, PF-06426779, RO1138452, and IRAK-1-4 Inhibitor specifically target IRAK4. By disrupting IRAK4 kinase activity, these inhibitors directly impact IRAK-M downstream, altering the balance between pro- and anti-inflammatory signals. MyD88 Inhibitor II acts indirectly by blocking MyD88, an upstream regulator of IRAK-M expression. This inhibition disrupts the anti-inflammatory function of IRAK-M, contributing to an enhanced pro-inflammatory state within the immune system. In summary, the chemical class of IRAK-M inhibitors comprises a spectrum of compounds that either directly or indirectly modulate IRAK-M, influencing its role in immune regulation. These inhibitors target key components of the TLR signaling pathway, disrupting IRAK-M expression and function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Resatorvid | 243984-11-4 | sc-476758 | 5 mg | $367.00 | ||
TAK-242 (Resatorvid) is a small-molecule inhibitor of Toll-like receptor 4 (TLR4) signaling. It directly inhibits IRAK-M by preventing its association with TLR4, disrupting downstream signaling cascades. This interference hinders the anti-inflammatory function of IRAK-M, leading to enhanced pro-inflammatory responses and immune activation. | ||||||
BX 795 | 702675-74-9 | sc-281689 sc-281689A sc-281689C sc-281689B sc-281689D sc-281689E | 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg | $219.00 $273.00 $331.00 $495.00 $882.00 $1489.00 | 5 | |
BX-795 is an inhibitor of TANK-binding kinase 1 (TBK1) and IKKε, key regulators of the TLR signaling pathway. By blocking TBK1 and IKKε, BX-795 indirectly influences IRAK-M expression and function, as these kinases contribute to IRAK-M regulation. This indirect inhibition results in altered anti-inflammatory responses, impacting the overall immune balance and promoting pro-inflammatory signaling. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 is an inhibitor of nuclear factor-kappa B (NF-κB) activation. It indirectly modulates IRAK-M by preventing NF-κB-dependent transcription of IRAK-M gene expression. This indirect inhibition alters the anti-inflammatory function of IRAK-M, leading to enhanced NF-κB activity and pro-inflammatory responses. BAY 11-7082 acts upstream to influence IRAK-M expression and regulatory functions in the context of immune response. | ||||||
Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor Inhibitor | 509093-47-4 | sc-204013 | 5 mg | $163.00 | 2 | |
IRAK-1-4 Inhibitor is a small-molecule inhibitor of IRAK1 and IRAK4. It directly targets the kinase activity of both IRAK1 and IRAK4, disrupting downstream signaling cascades. This direct inhibition leads to reduced IRAK-M expression and function, altering the balance between pro- and anti-inflammatory signals and enhancing immune responses. IRAK-1-4 Inhibitor's dual specificity makes it a comprehensive inhibitor within the IRAK-M regulatory network. | ||||||